Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 10, 2005, Pages 5684-5691

  Barkan, Ariel L ^a,i   Burman, Pia ^b   Clemmons, David R ^c   Drake, William M ^d,e   Gagel, Robert F ^f   Harris, Philip E ^b   Trainer, Peter J ^e   Van Der Lely, Aart Jan ^g   Vance, Mary Lee ^h  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^e CHRISTIE HOSPITAL   (United Kingdom)

^f UNIVERSITY OF TEXAS   (United States)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

ⁱ UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C;

ACROMEGALY; ADENOMA; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIABETES MELLITUS; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GALLBLADDER DISEASE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEART INFARCTION; HUMAN; INJECTION SITE REACTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TUMOR VOLUME; VERTEBRAL CANAL STENOSIS;

ACROMEGALY; ADENOMA; ADOLESCENT; ADULT; AREA UNDER CURVE; BLOOD GLUCOSE; DELAYED-ACTION PREPARATIONS; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMAN GROWTH HORMONE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PITUITARY NEOPLASMS;

EID: 26244464853     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-0331     Document Type: Article

References (29)

1. Melmed S, Jackson I, Kleinberg D, Klibanski A 1998 Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 83:2646-2652
2. Harris AG 1996 Acromegaly: epidemiology, etiology, and classification. In: Daly AF, ed. Acromegaly and its management. Philadelphia: Lippincott-Raven; 17-19
3. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S 2000 Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526-529
4. Clemmons DR 2004 The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. J Clin Invest 113:25-27
5. Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG 1994 Acromegaly: clinical and biochemical features in 500 patients. Medicine 73:233-240
6. Barrande G, Pittino-Lungo M, Coste J, Ponvert D, Bertagna X, Luton JP, Bertherat J 2000 Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 85:3779-3785
7. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez J-M, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P., Paramo C, Pico A, Torres E, Varela C, Vazquez J-A, Zamora J, Albareda M, Gilabert M, on behalf of the REA participants 2004 Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA). Eur J Endocrinol 151:439-446
8. Kreze A, Kreze-Spirova E, Mikulecky M 2001 Risk factors for glucose intolerance in active acromegaly. Braz J Med Biol Res 34:1429-1433
9. Fukuda I, Hizuka N, Murakami Y, Itoh E, Yasumoto K, Sata A, Takano K 2001 Clinical features and therapeutic outcomes of 65 patients with acromegaly at Tokyo Women's Medical University. Intern Med 40:987-992
10. Bertoli A, Magnaterra R, Borboni P, Marini MA, Barini A, Fusco A, Bollea MR 1998 Dose-dependent effect of octreotide on insulin secretion after OGTT in obesity. Horm Res 49:17-21
11. Ronchi C, Epaminonda P, Cappiello V, Beck-Peccoz P, Arosio M 2002 Effects of two different somatostatin analogs on glucose tolerance in acromegaly. J Endocrinol Invest 25:502-507
12. Parkinson C, Drake WM, Roberts ME, Meeran K, Besser GM, Trainer PJ 2002 A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J Clin Endocrinol Metab 87:1797-1804
13. Baldelli R, Battista C, Leonetti F, Ghiggi M-R, Ribaudo M-C, Paoloni A, D'Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V, Tamburrano G 2003 Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol (Oxf) 59:492-499
14. Quabbe HJ, Plockinger U 1989 Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly. J Clin Endocrinol Metab 68:873-881
15. Drake WM, Rowles SV, Roberts ME, Fode FK, Besser GM, Monson JP, Trainer PJ 2003 Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol 149:521-527
16. Lundin P, Pedersen F 1992 Volume of pituitary macroadenomas: assessment by MRI. J Comput Assist Tomogr 16:519-528
17. Segerlantz M, Bramnert M, Manhem P, Laurila E, Groop LC 2001 Inhibition of the rise in FFA by acipimox partially prevents GH-induced insulin resistance in GH-deficient adults. J Clin Endocrinol Metab 86:5813-5818
18. Norrelund H, Nair KS, Nielsen S, Frystyk J, Ivarsen P, Jorgensen JOL, Christiansen JS, Moller N 2003 The decisive role of free fatty acids for protein conservation during fasting in humans with and without growth hormone. J Clin Endocrinol Metab 88:4371-4378
19. Kasayama SOM, Takagi M, Saito H, Sumitani S, Kouhara H, Koga M, Saitoh Y, Ohnishi T, Arita N 2000 Impaired β-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 52:549-555
20. Plockinger U, Holst JJ, Messerschmidt D, Hopfenmuller W, Quabbe HJ 1999 Octreotide suppresses the incretin glucagon-like peptide (7-36) amide in patients with acromegaly or clinically nonfunctioning pituitary tumors and in healthy subjects. Eur J Endocrinol 140:538-544
21. van der Lely AJ, Hutson R, Trainer PJ, Besser GM, Barkan A, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hacker S, Zib K, Davis RJ, Scarlett JA, Thorner MO 2001 Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754-1759
22. Rose DR, Clemmons DR 2002 Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm IGF Res 12:418-424
23. UK Prospective Diabetes Study Group 1991 UK prospective diabetes study (UKPDS). VIII. Study design, progress and performance. Diabetologia 34:877-890
24. Fuller JH, Stevens LK, Wang SL 2001 Risk factors for cardiovascular mortality and morbidity: the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44(Suppl 2):S54-S64
25. Holdaway IM, Rajasoorya RC, Gamble GD 2004 Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667-674
26. Colao A, Baldelli R, Marzullo P, Ferretti E, Ferone D, Gargiulo P, Petretta M, Tamburrano G, Lombardi G, Liuzzi A 2000 Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 85:193-199
27. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ 2000 Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-1177
28. Ezzat S, Redelmeier DA, Gnehm M, Harris AG 1995 A prospective multicenter octreotide dose response study in the treatment of acromegaly. J Endocrinol Invest 18:364-369
29. Stewart PM, Stewart SE, Clark PM, Sheppard MC 1999 Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR). Clin Endocrinol (Oxf) 50:295-299